Directed Evolution Generates a Novel Oncolytic Virus for the Treatment of Colon Cancer by Kuhn, Irene et al.
Directed Evolution Generates a Novel Oncolytic Virus for
the Treatment of Colon Cancer
Irene Kuhn
1, Paul Harden
1, Maxine Bauzon
1, Cecile Chartier
1, Julie Nye
1, Steve Thorne
2, Tony Reid
2,
Shaoheng Ni
3, Andre Lieber
3, Kerry Fisher
4, Len Seymour
4, Gabor M. Rubanyi
1, Richard N. Harkins
1,
Terry W. Hermiston
1*
1Novel Technologies, Bayer Healthcare, Richmond, California, United States of America, 2Palo Alto Veteran’s Hospital and Stanford University, Palo Alto, California, United
States of America, 3Division of Medical Genetics, Department of Medicine, University of Washington, Seattle, Washington, United States of America, 4Hybrid systems Ltd,
Oxfordshire, United Kingdom
Abstract
Background: Viral-mediated oncolysis is a novel cancer therapeutic approach with the potential to be more effective and
less toxic than current therapies due to the agents selective growth and amplification in tumor cells. To date, these agents
have been highly safe in patients but have generally fallen short of their expected therapeutic value as monotherapies.
Consequently, new approaches to generating highly potent oncolytic viruses are needed. To address this need, we
developed a new method that we term ‘‘Directed Evolution’’ for creating highly potent oncolytic viruses.
Methodology/Principal Findings: Taking the ‘‘Directed Evolution’’ approach, viral diversity was increased by pooling an
array of serotypes, then passaging the pools under conditions that invite recombination between serotypes. These highly
diverse viral pools were then placed under stringent directed selection to generate and identify highly potent agents.
ColoAd1, a complex Ad3/Ad11p chimeric virus, was the initial oncolytic virus derived by this novel methodology. ColoAd1,
the first described non-Ad5-based oncolytic Ad, is 2–3 logs more potent and selective than the parent serotypes or the most
clinically advanced oncolytic Ad, ONYX-015, in vitro. ColoAd1’s efficacy was further tested in vivo in a colon cancer liver
metastasis xenograft model following intravenous injection and its ex vivo selectivity was demonstrated on surgically-
derived human colorectal tumor tissues. Lastly, we demonstrated the ability to arm ColoAd1 with an exogenous gene
establishing the potential to impact the treatment of cancer on multiple levels from a single agent.
Conclusions/Significance: Using the ‘‘Directed Evolution’’ methodology, we have generated ColoAd1, a novel chimeric
oncolytic virus. In vitro, this virus demonstrated a .2 log increase in both potency and selectivity when compared to ONYX-
015 on colon cancer cells. These results were further supported by in vivo and ex vivo studies. Furthermore, these results
have validated this methodology as a new general approach for deriving clinically-relevant, highly potent anti-cancer
virotherapies.
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Introduction
The development of effective treatments for human solid tumors
remains a significant challenge to cancer researchers and
oncologist alike. This is due to the complexity of human solid
tumors, with multiple, sometimes redundant, interacting signaling
pathways [1], patient population differences [2], and the ability to
acquire resistance to treatments including the newly developed
targeted molecular therapies such as erlotinib, gefitinib, and
imatinib [3]. Consequently, new agents, with unique mechanisms
of action capable of confronting this complexity, are needed.
Oncolytic viruses are unique anti-cancer agents capable of
amplifying the input dose through replication in a tumor-
dependent fashion. Human adenovirus (Ad) is one of a series of
viruses being developed as oncolytic agents to treat human
malignancies [4]. Early clinical trials and pre-clinical studies have
demonstrated synergy of this type of novel cancer therapy with
standard of care chemotherapy [5] and radiation [6,7,8].
However, while the oncolytic Ads tested in clinical trials have
demonstrated marked safety, they have shown limited clinical
efficacy as monotherapies [9,10,11,12]. Consequently, several
approaches are being explored to increase their potency (defined
as the viruses ability to replicate, lyse cells, and spread), including
increasing the efficiency of cell lysis [13,14,15,16,17,18], infectivity
[19], and ‘‘arming’’ them with therapeutic transgenes [20].
There are 51 defined human Ad serotypes, grouped A–F and
these serotypes differ at a variety of levels (e.g. pathology in
humans and rodents, hemagglutinatin properties, cellular recep-
tors). However, with the exception of fiber alterations [19],
alternative human Ad serotypes to the well studied Ad5 serotype
have been ignored. Thus alternative serotypes may represent an
unexplored avenue for developing more potent virotherapies.
PLoS ONE | www.plosone.org 1 June 2008 | Volume 3 | Issue 6 | e2409To fully explore their potential, we employed a methodology we
term ‘‘Directed Evolution’’, in which pools of Ad serotypes,
representing the different Ad subgroups, are passaged on human
tumor cell lines representative of major solid tumor indications
(breast, colon, pancreatic, prostate) to invite recombination and
selection of potent viral variants or serotypes. This simple, non-
prejudiced approach utilizes the complexity of the human tumor
cell to direct the evolution of select, highly potent Ads from the pool
and is very appealing since it can be directed toward an outcome
(e.g. developing a more lytic virus) without prejudice towards the
mechanism(s) that may be responsible for that outcome (e.g.
efficiency of cell lysis, infectivity, viral DNA replication). ColoAd1, a
virus isolated from the colon cell line-passaged viral pool, displayed
potency superior to Ad5 on a series of colon tumor cell lines, and a
wider therapeutic window on a collection of colon tumor lines and
primary normal cells than the recently approved and marketed
virotherapy, ONYX-015/H101[21]. The superior potency was
further demonstrated in vivo in a liver tumor seeding model and the
selectivity was validated on clinically excised colon cancer tissue. In
addition, we demonstrate that we can ‘‘arm’’ this novel agent by
incorporating transgenes into the viral genome without compro-
mising potency of the agent, thus increasing the potential of this
agent to deal with the complexity of human solid tumors. This is the
first description of a non-Ad5 based oncolytic Ad, and the
exploitation of alternative Ad serotypes marks a novel approach
to the development of more potent and selective oncolytic viruses
for the treatment of human cancers.
Results
Directed Evolution of pooled adenovirus serotypes on
different tumor cell lines derives distinctly different viral
pools that are superior in potency to Ad5
The Directed Evolution strategy outlined in the Materials and
Methods (Figure 1A) is an unbiased approach to determine whether
alternative serotypes, or recombinants thereof, are superior in
potency to Ad5 (the serotype of all current oncolytic Ads) on human
cancercelllines.Asalow-resolutionmethodtotrackchangesduring
passage of the viral pool and to characterize the homogenous/
heterogenous nature of the final viral pool, the pools were examined
on a TMAE anion exchange column exploiting viral capsid charge
differences associated with each serotype (Figure 1B). Each viral
pool collected from the different cell lines after passage 20 eluted as
a single peak with distinct retention time (Figure 1C). Each elution
peak of a passaged viral pool appeared to track with one of the
original serotypes (Figure 1B). This suggests that all viruses are not
equal in their potency on a given tumor cell line and that differences
in tumor cell lines can select for specific viruses in a mixed virus
pool. Since at least two of these selected viral pools did not track
with the Ad5 retention time, Ad5 is not (based on potency) the best
virus for deriving all oncolytic Ads.
An MTS assay was employed to compare the potency of the
different selected viral pools to the original mixed serotype pool
and to Ad5. All selected viral pools increased in potency relative to
Ad5 or the starting pool, with the magnitude of the increase
varying significantly between the pools. The greatest increase in
potency relative to Ad5 was observed in the pool passaged on the
colon tumor cell line HT-29 (approximately 2 log increase) with
the smallest increase (1.2 fold) noted in the pool derived from
passage on the MDA-231mt1 cell line (Table 1).
ColoAd1 is a highly potent and selective oncolytic virus
Since the viral pool passaged on HT-29 cells displayed the
greatest increase in potency on its cognate cell line, viruses within
this pool were pursued for further characterization. Individual
plaque-purified viruses were isolated and screened by MTS assay
for their lytic potential on the HT-29 tumor cell line. The potency
of individual plaques was compared to that of the HT-29 pool
from which they were isolated. The plaque-purified viruses were
found to be equal to or greater in potency than the HT-29 pool.
The most potent of these plaque-purified viruses, termed Co-
loAd1, was chosen for further characterization.
While ColoAd1 was selected for growth on the colon tumor cell
line HT-29, it was not clear whether this virus had increased
potency on all tumor cell lines, was selective for colon cancer
tumor cell lines, or was more potent on all cell types including
primary normal cells. To address the first two questions, ColoAd1
was tested by the MTS assay on all of the original tumor cell lines
used in this study (Panc1-sct, MDA-231mt1, HT-29, and PC-3),
two additional tumor cell lines (OVCAR-3, DU-145), and on a
panel of colon tumor cell lines (DLD-1, LS1034, HCT116,
LS174T, SW48, SW403, Colo320DM), comparing it to Ad5.
ColoAd1 was over 2 logs more potent than Ad5 on the cognate
cell line, HT-29. Additionally, ColoAd1 demonstrated potency
equal to or greater than Ad5 on some human tumor cell lines (e.g.
PC-3, MDA-231, Ovcar-3, and DU-145), but was attenuated
(about two logs less potent than Ad5) on the Panc1 cell line
(Table 2). ColoAd1 displayed significantly increased potency (9 to
100 fold) relative to Ad5 on all colon cancer tumor cell lines
screened, with the exception of Colo320DM (Table 3). This
suggests that colon tumor cell lines have properties that make them
significantly susceptible to infection and lysis by ColoAd1.
To test whether ColoAd1 was selective for tumor cells over
normal cells and thus, by definition, an oncolytic virus, ColoAd1
was examined in two different colon tumor cell lines (HT-29,
DLD-1), and on primary endothelial and epithelial cells (HUVEC,
HMEC) comparing its potency in each MTS assay to Ad5 and
ONYX-015/H101. The results show that ONYX-015 and Ad5
are significantly less potent than ColoAd1 on the HT-29 and
DLD-1 cell lines (Table 4). In contrast, the potency of ColoAd1 on
HUVEC cells was the same as Ad5 and slightly more potent than
ONYX-015 (Table 4). On HMEC cells, ColoAd1 was less potent
than Ad5 and ONYX-015 (Table 4). To quantitate these
differences between ColoAd1, ONYX-015, and Ad5, an in vitro
therapeutic window was calculated, defined as the ratio of the IC50
of a given virus on normal cells, HUVEC or HMEC, divided by
the IC50 on the colon tumor cell lines HT-29 or DLD-1 (Table 2).
These calculations establish that ColoAd1 has a therapeutic
window that is 3 to 4 logs greater than that of Ad5 or ONYX-015/
H101 in these in vitro assays.
ColoAd1 is a chimeric virus that displays enhanced
potency over its parent virus, Ad11p
Chromatographic analysis indicated that the major coat
proteins of ColoAd1 were derived from Ad11p, a group B virus.
To determine the relationship between ColoAd1 and Ad11p, the
virus was sequenced, revealing that ColoAd1 is Ad11p, with a
nearly complete E3 region deletion, a smaller deletion in the E4
region, and a chimeric Ad3/Ad11p E2B region (Figure 2).
It is possible that Ad11p or Ad3 are serotypes that are inherently
more potent, and have a wider therapeutic window, than Ad5, and
that this property is independent of the acquired genetic changes
found in the ColoAd1 genome. To test this, we examined
ColoAd1, Ad11p and Ad3 on the two colon tumor cell lines, HT-
29 and DLD-1, and on primary human endothelial and primary
human epithelial cells, HUVEC and HMEC, respectively, by
MTS assay. As presented in Table 4, ColoAd1 exhibited superior
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demonstrating that this recombinant virus was superior in potency
to both of its parent viruses. Interestingly, Ad11p, and not Ad3,
displayed an inherent therapeutic window as defined here via
MTS analysis. Thus, ColoAd1 is a derivative of Ad11p whose
differences with Ad11p enhance the potency of the virus without
altering the serotype’s natural ability to selectively replicate in
tumor cells versus primary normal cells.
Figure 1. The Directed Evolution process and analysis of viruses and derivative viral pools by anion-exchange chromatography. A,
Representation of the Directed Evolution process (see Materials and Methods for detailed description). B, Chromatograms of each pure Ad serotype
included in the mixed serotype starting pool from which ColoAd1 was selected. C, Chromatograms of the passage 20 viral pools derived on the HT-
29, Panc-1, MDA-231, and PC-3 tumor cell lines, respectively. The differing retention times of these pools are consistent with the predominant
serotype of the pool being Ad5 or Ad40 for the Panc-1 pool, Ad11p for the HT-29 pool, Ad3 or Ad4 for the PC-3 pool, and Ad5 or Ad40 for the MDA-
231 pool.
doi:10.1371/journal.pone.0002409.g001
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Ad11p is low [22,23] The greatest need for this type of therapeutic
is in patient populations where the tumor has progressed to a
systemic, metastatic cancer. Thus treating patients with an agent
that lacks pre-existing immunity should enhance the opportunity
for the agent to circulate and eliminate metastatic tumor cells. To
confirm the previous reports of low seroprevalence of Ad11p,
serum from six different individuals was collected and tested for
the ability to neutralize the infectivity and lytic potential of these
viruses on a reporter cell line, Ovcar-3. In agreement with the
literature, the serum demonstrated little effect on ColoAd1 (data
not shown), suggesting that ColoAd1 may be a viable approach for
the systemic treatment of colon cancer.
ColoAd1 has anti-tumor activity superior to ONYX-015
and Ad11p in a colon cancer liver tumor seeding
xenograft mouse model following i.v. administration
Most solid tumors are metastatic at the time of diagnosis. Since
the initial site of metastasis for colon cancer is the liver, a colon
cancer liver tumor seeding model [24] was used to examine the in
vivo efficacy of ColoAd1. To determine first whether viral anti-
tumoral activity is dependent upon the ability of the virus to
replicate and spread in this model, a dose response study was
conducted comparing ColoAd1 to a replication-defective form of
ColoAd1 (where the essential E1 region of the virus was deleted).
As seen in Figure 3A, systemically delivered ColoAd1 significantly
decreases tumor burden in a dose, and replication, dependent
fashion. Since HT-29 cells shed carcinogenic embryonic antigen
(CEA), this can be used as an easily measured surrogate for tumor
burden. Importantly, measurements of CEA in the bloodstream
(Figure 3B) correlated well with the results of tumor-weight
measurements (Figure 3A).
To test whether the superior in vitro potency of ColoAd1 relative
to Ad11p and ONYX-015/H101 was recapitulated in vivo, these
viruses were compared in the liver tumor seeding model. As seen
in Figure 3C (tumor weight) and Figure 3D (CEA level
measurements), the anti-tumoral activity of ColoAd1 was superior
to both Ad11p and ONYX-015 in this model, corroborating the in
vitro conclusions.
Table 1. Potency of viral pools relative to Ad5 on cognate cell
lines.
Cell Line Virus IC50 (Vp/cell)
Potency
(Relative to Ad5)
HT-29 Ad5 20
Wt0 20 1
HT29(Wt20) .03 667
PC-3 Ad5 40
Wt0 8.0 5
PC-3(Wt20) 9.5 4.2
MDA231 Ad5 30
Wt0 80 .37
MDA231(Wt20) 25 1.2
Panc-1 Ad5 9.5
Wt0 15 .07
Panc-1(Wt20) 3.5 2.7
Potency values less than 1 indicates attenuation relative to Ad5.
The potency of each viral pool that underwent 20 passages of Directed
Evolution (Wt20) was compared to the starting pool (Wt0) and to Ad5 on their
respective cognate cell line. Viral potencies were measured by MTS assay.
doi:10.1371/journal.pone.0002409.t001
Table 2. Potency of ColoAd1 relative to Ad5 on a panel of
cancer cell lines.
Cell Line Virus IC50 (Vp/cell)
Potency
(Relative to Ad5)
HT-29 Ad5 73 1282
ColoAd1 0.06
PC-3 Ad5 11 48
ColoAd1 0.23
MDA231 mt1 Ad5 17 3
ColoAd1 5
Ovcar-3 Ad5 18 1.5
ColoAd1 12
DU145 Ad5 1 1
ColoAd1 0.84
Panc-1 Ad5 0.05 0.02
ColoAd1 3
Potency values less than 1 indicates attenuation relative to Ad5.
Potency of ColoAd1 on a mixed panel of tumor cell lines. The potencies of
ColoAd1 and Ad5 were measured by MTS on the mixed panel of tumor cell lines
to derive an IC50 value for each virus. These IC50 values were used to derive the
potency of ColoAd1 relative to Ad5 using the calculation IC50 value Ad5 divided
by the IC50 value of ColoAd1 on the same cancer cell line.
doi:10.1371/journal.pone.0002409.t002
Table 3. Potency of ColoAd1 relative to Ad5 on a panel of
colon cancer cell lines.
Cell Line Virus IC50 (Vp/cell)
Potency
(Relative to Ad5)
HT-29 Ad5 73 1282
ColoAd1 0.06
DLD-1 Ad5 35 100
ColoAd1 0.35
LS1034 Ad5 8 38
ColoAd1 0.21
HCT116 Ad5 0.72 36
ColoAd1 0.02
LS174T Ad5 13 23
ColoAd1 0.57
SW48 Ad5 1 17
ColoAd1 0.06
SW403 Ad5 9 9
ColoAd1 1
Colo320DM Ad5 3 0.03
ColoAd1 *r2 value 0.82 105
Potency values less than 1 indicate attenuation relative to Ad5.
Potencies of ColoAd1 and Ad5 were measured by MTS on the mixed panel of
tumor cell lines to derive an IC50 value for each virus. These IC50 values were
used to derive the potency of ColoAd1 relative to Ad5 using the calculation IC50
value Ad5 divided by the IC50 value of ColoAd1 on the same colon tumor cell
line.
doi:10.1371/journal.pone.0002409.t003
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from colon cancer patients
In vitro and in vivo models that accurately predict clinical efficacy
have been difficult to identify, and the lack of such prognostic
models continues to result in extensive attrition of cancer drugs.
Consequently, freshly isolated, surgically excised human colon
cancer material was examined as an additional model system for
testing ColoAd1. Since surgical material includes both tumor
tissue and normal cell margins, this system offers an excellent
opportunity to test the tumor selectivity of the virus in the context
of intact human tissue. The viability of a series of tumor samples
was analyzed in tissue culture; viability varied from 2 to 6 days.
Consequently, to ensure that cell death was due to virally induced
lysis and release of progeny virus and was not due to spontaneous
lysis of the surgical material, a 24 hr endpoint was selected. Six
tumor samples were collected and punch cultures from tumor and
normal sections (as determined by a clinical pathologist) were
generated and exposed to either Ad5 or ColoAd1. To determine
each viruses’ ability to replicate, lyse and release infectious virus,
supernatant was collected 24 hr post-infection and assayed for the
Table 4. Potency and therapeutic indices of ColoAd1.
Cell Line Virus IC50 (Vp/cell)
Potency (Relative
to Ad5)
Therapeutic Index
(IC50 HUVEC/IC50 HT-29)
Therapeutic Index
(IC50 HMEC/IC50 HT-29)
HUVEC Ad5 36
Ad3 799 0.05
Onyx-015/H101 391 0.1
Ad11p 399 0.1
ColoAd1 50 0.7
HMEC Ad5 26
Ad3 43 0.6
Onyx-015/H101 9 3
Ad11p 940 .03
ColoAd1 575 .05
HT-29 Ad5 11 3 2
Ad3 45 0.2 18 1
Onyx-015/H101 140 0.1 3 .06
Ad11p 1.9 6 214 495
ColoAd1 .02 650 2500 28750
DLD-1 Ad5 5 7 5
Ad3 1162 0.004 0.7 .04
Onyx-015/H101 461 0.01 0.8 .02
Ad11p 4 1 100 235
ColoAd1 .03 167 1667 19167
Potency values less than 1 indicates attenuation relative to Ad5.
The potencies of ColoAd1, Ad5, ONYX-015, Ad3 and Ad11p on colon cancer (HT-29, DLD-1) and normal cells (HUVEC, HMEC) were measured by MTS assay at day 4 post-
infection and is represented in the table as an IC50 value. The potency (as reflected in the IC50) is the ratio of the IC50 of a given virus on a given cell line relative to Ad5’s
IC50 on that cell line. The Therapeutic Index was calculated using either HUVEC (primary endothelial) or HMEC (primary epithelial) cells and using the ratio of the IC50 of a
virus on these primary, normal cells and dividing it by its IC50 on HT-29 tumor cells.
doi:10.1371/journal.pone.0002409.t004
Figure 2. Genomic sequence diagram of ColoAd1. The genomic differences between ColoAd1 and Ad11p are noted in the schematic. In the
E2B region there are frequent substitutions of Ad3 sequences for Ad11p sequences between base pairs 6081 and 9322. In addition, ColoAd1 has a
nearly complete (2,444 bp) E3 region deletion, and a smaller (25 bp), second deletion that maps to a putative E4orf4 region of the virus.
doi:10.1371/journal.pone.0002409.g002
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generated approximately two logs more viral progeny on tumor
material than on matched normal tissue, confirming its tumor
selective replication in freshly isolated human tumor tissue. These
studies also demonstrated that ColoAd1 exhibited at least one log
higher tumor selectivity than the control virus, Ad5.
CD46 has been identified as a cellular attachment receptor for
Ad11p, the parent virus of ColoAd1 [25,26]. To better define the
expression of CD46 in primary and metastatic colon cancer, we
examined colon cancer material, normal liver tissue and normal
colon tissue for CD46 expression by immunohistochemistry (IHC)
(Figure 4B). Strong CD46 IHC staining was consistently seen in
colon cancer tissue, but was absent or generally weak in normal
colon and liver tissue. This suggests that CD46 expression may be
a contributing factor to the observed tumor selectivity of ColoAd1
and thus may be a potential tool for pre-screening patients for
treatment with this therapeutic agent.
ColoAd1 can be armed without compromising potency
Armed oncolytic viruses seek to complement the potency of the
oncolytic virus by the addition of therapeutic transgenes [20]. In
this approach it is important that a therapeutic transgene insertion
site within the viral genome be identified that does not
compromise the life cycle and therefore the potency of the virus.
Unlike Ad5, where the biology and description of insertion sites
compatible with the viral life-cycle are well described, ColoAd1
represents a novel agent that is primarily derived from the poorly
studied Ad11p genome. Consequently, a transposon-based system
that can scan the genome for insertion sites in a non-prejudiced
fashion was utilized for the identification of compatible transgene
insertion sites [27] Given that the viral genome coding capacity of
the human Ad is constrained [28] a consensus splice acceptor site
was placed upstream of the transgene, eliminating the need for an
exogenous promoter and linking expression to an endogenous
ColoAd1 promoter [29]. To enhance the ability to identify
transgene expressing ColoAd1 variants, GFP was chosen as the
transgene. A number of viral isolates were generated and then
screened for potency and a virus termed ColoAd1-GFP was
selected based on equivalent potency to the parent ColoAd1
(Fig. 5A and 5B).
Past studies using a splice acceptor-based expression cassette
demonstrated that expression occurred late in the viral life cycle
and was dependent upon viral DNA replication [29]. Linking
therapeutic transgene expression to the selectivity of the virus has a
Figure 3. Anti-tumoral activity of ColoAd1 after systemic administration in a liver metastasis xenograft mouse model. HT-29 colon
cancer cells were seeded to the liver of nude beige mice (n=10 mice per treatment group). Plasma CEA level was used to monitor tumor
establishment. A and B, Mice were treated by tail-vein (i.v.) injection with 1610
10,5 610
10,o r1 610
11 total viral particles of ColoAd1 per mouse. A
fourth set of liver-tumor-bearing mice were i.v. injected with 1610
11 total viral particles of a replication-defective [E1
(2)] version of ColoAd1,
ColoAd1CJ132. A fifth set of mice were injected with vehicle control (buffer). Tumor weight measurements demonstrate that ColoAd1 has anti-
tumoral activity, which is dose-dependent (A). Blood CEA levels at the end of the study (day 12 post viral administration) corroborate the tumor
weight data (B). C and D, Comparison of anti-tumoral activity of ColoAd1, Ad11p and ONYX-015 in the HT-29 liver metastasis xenograft mouse model.
In a second study performed in the same model as in Panels A and B, ColoAd1 was compared to its parental virus, Ad11p, and to the clinically-
approved oncolytic virus ONYX-015; each virus dosed i.v. to a total of 1610
11 viral particles per mouse.
doi:10.1371/journal.pone.0002409.g003
A Novel Virus for Colon Cancer
PLoS ONE | www.plosone.org 6 June 2008 | Volume 3 | Issue 6 | e2409significant safety advantage over traditional constitutive expression
systems since gene expression would be limited and dependent
upon the tumor selectivity of the viral system [30]. To determine
the GFP expression kinetics from ColoAd1-GFP, HT-29 cells were
infected in the presence or absence of AraC, a compound which
inhibits viral replication. As seen in Figures 5C and 5D, the GFP
expression was blocked by the addition of AraC indicating that
expression occurs late in the viral life cycle and is linked to viral
replication.
Discussion
In the present study we established conditions that select potent
viral agents, without bias towards any mechanism, from a pool of
Figure 4. Ex vivo potency and selectivity of ColoAd1. A, Punch samples of freshly-excised human colon tumors (n=6) and matched normal
margin areas, were infected with either ColoAd1 or Ad5 and maintained in tissue culture. The viral burst from each sample was measured by plaque
assay at 24 hours post infection. B, Immunohistochemical staining for CD46 present in clinical colon tumor, normal colon, and normal liver samples.
doi:10.1371/journal.pone.0002409.g004
Figure 5. Potency and kinetics of armed virus, ColoAd1-GFP. MTS assays were performed on ColoAd1 and ColoAd1-GFP on A) the colon
tumor cell line, HT-29 and B) the primary endothelial cells, HUVEC. The reporter gene, GFP, is expressed with late kinetics (ie., is dependent upon the
initiation of viral DNA replication for expression) as defined by expression C) only in the absence of AraC and D) lack of expression in the presence of
AraC.
doi:10.1371/journal.pone.0002409.g005
A Novel Virus for Colon Cancer
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is a highly accelerated version of the natural selection of viruses,
can be applied to any virus and any cancer type of choice.
Using this process, we generated and characterized ColoAd1, a
novel Ad3/Ad11p chimeric oncolytic virus for the treatment of
human colon cancer and, potentially, other indications. This virus
was shown to be more potent and have a larger therapeutic
window than Ad5 and the most clinically advanced oncolytic virus
Onyx-015 (Tables 2–4). Futhermore, ColoAd1 demonstrated
increased potentcy in an intravenous tumor model and on tumor
explants (Figures 3 and 4).This virus has several changes relative to
the parent Ad11p virus, including a chimeric E2B region and
deletions in the E3 and E4 regions. Which change or changes play
a role in the enhanced potency of this virus is not clear. The loss of
genes in the Ad5 E3 region has been shown in group B Ads to
enhance viral lysis and spread [31] by an undefined mechanism.
The E2B region encodes the pre-terminal protein (pTP) and the
viral DNA polymerase (DNA pol), two of the three E2-encoded
proteins necessary for viral DNA replication. The terminal 18 bp
of the viral genome, considered the minimal replication origin,
directly interacts with the pTP and DNA pol heterodimer. It is
important to note that when sequenced the genomic ends of
ColoAd1 and the wild type Ad11p were identical to those of Ad3
and conflicted with the described DNA sequence termini
described for Ad11p [32,33]. Thus, the E2B alterations in
ColoAd1 may generate a pTP-DNA pol heterodimer that is more
compatible with the terminal 18bp of ColoAd1 than the original
Ad11p pTP-DNA pol. Coupled with ColoAd1’s smaller genome (a
result of genomic deletions) this virus may replicate more quickly
and also reach a critical viral burst size more rapidly, consequently
enhancing viral lysis and spread.
With regard to selectivity, studies with the pTP of Ad5 have
shown that it interacts with CAD, a host protein responsible for
the TP-nuclear matrix association. The level of CAD is correlated
with the rate of cell division; two to five-fold higher levels in tumor
cells than in normal cells and almost non-existent in quiescent cells
[34,35]. Consequently, TP alterations and their potential interac-
tions with CAD (or similar proteins) may also be mechanisms of
enhanced replication and/or selectivity of the virus.
The third alteration in the ColoAd1 viral genome is a small
deletion (24 bp) that maps to the E4orf4 region of the virus. The
E4orf4 protein of Ad5 interacts with the host cell’s serine/
threonine protein phosphatase 2A (PP2A), [36]. This interaction
has been shown to induce p53-independent apoptosis, inactivate
splicing factors, and reduce E1A activation of AP-1, JunB, and
expression of the Ad E2 and E4 transcription units [37]. However,
since the E4 region is highly spliced, the E4orf4 gene deletion may
also alter the expression of another E4 gene in this complex
transcription unit, thus indirectly contributing to the enhanced
potency of ColoAd1. In addition, it is not clear that Ad11p and
Ad3 proteins maintain any or all of the functions ascribed to
homologous Ad5 proteins. Thus extrapolations of Ad5 protein
functions to proteins in ColoAd1 must be carefully tested.
Consequently, while it is clear that CololAd1 has undergone a
series of genetic alterations that result in a more potent virus, it is
not clear which alteration(s) are responsible for enhanced potency.
It is important to note that ColoAd1 is a member of the group B
Ads and thus distinctly different from the traditional Ad5-based
oncolytic viruses. It does not, for example, use the Ad5 receptor,
(coxsackie B- and adenovirus receptor, CAR), for attachment to
cells. Instead, ColoAd1 appears to employ at least two receptors
that are distinctly different from CAR [22,38,39], one of which has
been recently described as CD46 [25,26]. The significance of this
is emphasized by recent studies on clinical material showing that
CAR is poorly expressed on a variety of different tumor types and
that CAR expression decreases with the advance in stage and
grade of the tumor [40,41,42,43,44]. Additional reports of tumor
suppressor properties of CAR [45,46] and detection of soluble
CAR in the tumor microenvironment [47] call into question the
use of CAR-dependent adenoviruses for the treatment of all
human cancers. In contrast, tumor cell surface expression of
CD46, the putative ColoAd1 receptor, appears to increase with
stage and grade in a variety of cancers [48]. Thus, ColoAd1 may
have therapeutic utility beyond colon cancer, and studies to
investigate this are ongoing. Of additional importance are data
demonstrating that the seroprevalence of Ad11p is low [22,23].
Since the greatest need for this type of therapeutic is in patient
populations where the tumor has progressed from a confined local
disease to a systemic, metastatic cancer, treating patients with an
agent to which they do not have pre-existing immunity should
enhance the opportunity for the agent to circulate and eliminate
metastatic tumor cells. This is in contrast to Ad5 where sero-
prevalence, as measured by neutralizing antibodies, reaches levels
of approximately 50% in the general population [23,49].
It is important to note that the potency of ColoAd1 can be
complemented by one and potentially more therapeutic trans-
genes. The ability to arm these agents represents a unique
opportunity to impact the treatment of cancer on multiple levels
from a single agent. As demonstrated by the incorporation and
efficient expression of GFP from the ColoAd1 genome, arming
can occur without compromising the potency or selectivity of the
viral therapeutic. In addition to incorporating agents that
complement the oncolytic potential of the virus (e.g. prodrug
converting enzymes, anti-angiogenic factors, immunotherapeu-
tics,), arming creates the opportunity for clinicians to track the
activity of the virotherapy treatment in a minimally invasive
fashion [50]. This is made all the more meaningful if the method
for tracking the virotherapy is directly linked to the viral life-cycle.
In the case of ColoAd-GFP, this has clearly been demonstrated,
where GFP expression was demonstrated to be directly linked to
DNA replication (Figure 5B). Various genes have been identified
that would allow clinicians to track viral activity and include genes
associated with radionuclide imaging (e.g. HSV-1 TK, human
thyroidal sodium iodide symporter,[51,52] ) and soluble marker
peptides readily detectable in the bloodstream or via urine
sampling (e.g. human carcinoembryonic antigen, b-chain of
human chorionic gonadotropin [53,54,55]). Using the expression
of the linked gene as a biomarker of viral replication and spread
represents an opportunity for clinicians to personalize the
treatment, giving additional doses only as needed, thus moving
away from standard, timed dosages commonly associated with
current chemotherapy treatments. Equally important, as we
consider balancing the need for increased potency with safety of
the viral therapy, arming could also be used to incorporate a
‘‘safety valve’’ into the virotherapy, capable of aborting the viral-
based therapy through the administration of a clinically approved
drug (eg. incorporation of the HSV TK gene and administration
of gancyclovir). Importantly, the capacity to arm an oncolytic virus
creates an opportunity to build increased potency, safety or enable
more personalized medicine, a flexibility unique to this type of
anti-cancer agent.
Human oncolytic viruses to date have failed in the clinic due to
insufficient therapeutic efficacy as monotherapies. To address this,
we expanded our search beyond the traditional Ad5 serotype to a
series of Ad serotypes representing different viral subgroups.
Inviting recombination to increase biodiversity, then applying
selective pressure, we developed a unique oncolytic virus,
ColoAd1. Deriving oncolytic viruses via tumor selection from
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and the tumor. While we demonstrate the principle using
adenoviruses, the same approach may be applicable to other
viruses and represents a novel approach to develop more effective
virotherapies for the treatment of human tumors.
Methods
Viruses and Cell lines
The Ad serotypes Ad3 (GB strain), Ad4 (RI-67 strain), Ad5
(Adenoid 75 strain), Ad9 (Hicks strain), Ad16 (Ch. 79 strain) and
the tumor cell lines A549, PC-3, HT-29, DLD-1, LS1034,
HCT116, LS174T, SW48, SW403, Colo320DM, OVCAR-3,
DU-145 were all purchased from the ATCC. HEK293s were
licensed from McMaster Univeristy. MDA-231mt1 and Panc-sct
were derived from rapidly growing subcutaneously implanted
xenograft by Drs. Deb Zajchowski and Sandra Biroc at Berlex
Biosciences, respectively. Human umbilical vein endothelial cells
(HUVEC, Vec Technologies, Rensselaer, NY), and human
mammary epithelial cells (HMEC, Cambrex, Walkersville, MD)
were grown as per vendors instructions and Ad11p (Slobitski
strain), and Ad40 were kind gifts from Dr. William S.M. Wold at
St. Louis University. The replication defective ColoAd1 (bp 461–
3397 deleted so as to eliminate the E1A and E1B genes) was
derived by homologous recombination of ColoAd1 into a pBR-
derived plasmid in BJ5183 bacteria using methods as previously
described [56].
Viral Purification and Quantitation
Viral stocks were propagated on HEK293 cells, with the exception
of the replication-defective ColoAd1 which was propagated on A549
cells expressing the E1A and E1B regions of ColoAd1, and purified
on CsCl gradients [57,58]. The method used to quantitate and
partially characterize viral particles is based on that of Shabram et al
[59], with the exception that the anion-exchange media TMAE
Fractogel was used instead of Resource Q [60].
Cytolytic assay
The viral lytic capacity was measured using a modification of
the MTT assay [61]. Briefly, the MTS assay (CellTiter 96H
Aqueous Non-Radioactive Cell Proliferation Assay, Promega,
Madison, WI) was used in place of the MTT assay because
conversion of MTS by cells into aqueous, soluble formazan
reduces time and eliminates the use of a volatile organic solvent
associated with the MTT assay.
To perform the assay, cells were seeded at a density determined
for each tumor cell line to generate a confluent monolayer within
24 hr. These densely seeded cells were allowed to grow for two
additional days prior to exposure to the test virus(es). Infections of
both tumor and primary normal cells were carried out in
quadruplicate, using serial three fold dilutions of the viruses
starting at a particle per cell ratio of 100 and ending at a particle
per cell ratio of 0.005 with the exception of MTS assays on
HUVEC or HMEC cells which were done starting at a particle
per cell ratio of 10,000 for purposes of calculating an in vitro
therapeutic index. Infected cells were incubated at 37uC and the
MTS assay was performed at the time points indicated for the
individual primary cells or tumor cell lines. Mock-infected cells
served as negative controls and established the 100% survival
point for the given assay.
Directed Evolution and generation of ColoAd1GFP
Viral serotypes representing Ad subgroups B–F were pooled and
passaged twice on sub-confluent cultures of the target tumor cell
lines at a particle-per-cell ratio of approximately 200 to invite
recombination between serotypes (Figure 1A). Supernatants from
the second round of the high viral particle-per-cell infection of
subconfluent cultures were then used in a 10-fold dilution series to
infect confluent T-75 tissue culture flasks of target tumor cell lines
PC-3, HT-29, Panc-1 and MDA-231. To achieve confluency,
each cell line was seeded at split ratios that allowed that cell line to
reach confluency between 24 and 40 hours post seeding, and the
cells were allowed to grow a total of 72 hours post seeding prior to
infection. This was done to maximize the confluency of the cells
attempting to mimic growth conditions in human solid tumors.
The infected T75s were observed for the first signs of cytopathic
effect (CPE). In order to harvest the most potent viruses, cell culture
supernatant was harvested from the flask infected with the most
concentrated innocula in the 10-fold dilution series that did not
show any sign of CPE at day 3 or 4 post-infection. The assumption
was that only a small population of potent viruses would be
generated and these viruses would replicate, lyse the host cells and
be released into the supernatant before any gross morphological
changes could be detected. In the case of HT-29 and PC-3 cell lines,
this was modified for passages 10–20 to harvest of the second flask,
i.e. harvest 100-fold below the dilution in which CPE were
detectable by day 3 post-infection. Each harvest served as the
starting material for the successive passage of the virus. This process
was repeated until the viral pool achieved 20 passages.
Individual viruses were isolated from each passage 20 pool by
two rounds of plaque purification on A549 cells using standard
methods [57]. In brief, dilutions of the supernatant harvested from
the 20
th passage on each target tumor line were used to infect
A549 cells in a standard plaque assay. Individual plaques were
harvested, and the same plaque assay method was used to generate
a second round of individual plaques from these harvests. Plaques
from the second round of plaque purification were deemed pure,
infected cultures were prepared using these purified plaques, and
the potency of these culture supernatants determined by MTS
assay as described.
ColoAd1GFP was generated using a transposon-based arming
system as previously described [29]. Briefly, ColoAd1 genomic
DNA was isolated and cloned into a pBR-derived plasmid by
homologous recombination in BJ5183 bacteria to create plasmid
pCJ94. In pCJ94, the viral genome is flanked on both sides with
AsiSI restriction enzyme sites to allow the viral genome to be
excised from the plasmid back and thus enable efficient virus
rescue. Using transposition, an expression cassette containing a
consensus splice acceptor upstream of the green fluorescent
protein (GFP) gene was inserted at random sites throughout the
ColoAd1 genome within the pCJ94 plasmid. The recombinant
ColoAd1-GFP genomes where then isolated from a plasmid pool
by AsiSI restriction enzyme digestion and transfected into HEK-
293 cells [27]. Using a fluorescent microscope, GFP positive
plaques were picked and propogated in A549 cells. Three rounds
of plaque purification were performed. CPE stocks of 4
recombinant viruses were generated and titered by HPLC [60].
Of these 4 recombinant viruses a single clone, termed ColoAd1-
GFPdemonstrated potency equivalent to ColoAd1 as determined
by MTS assay on HT-29 and HUVEC cells as described. Clone
4cli2a was chosen for further study and termed ColoAd1-GFP.
Viral DNA replication dependent GFP expression from ColoAd1-
GFP was determined by assaying expression in the presence of the
DNA replication inhibitor AraC (Sigma Aldrich, St. Louis, MO).
DNA sequencing
Purified ColoAd1 and Ad11p DNA samples were sent to
Commonwealth Biotechnologies Inc. (CBI, Richmond, VA) for
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endonuclease Sau3 AI, and ‘‘shotgun’’ cloned into the plasmid
vector pBluescript II. Positive clones were propagated, the plasmid
isolated and sequenced using the sequencing primers M13R and
KS. Individual sequencing reactions were trimmed, edited and
assembled using Sequencher
TM (Gene Codes Corp.). Gaps in
coverage were amplified with custom oligonucleotide primers and
sequenced. The 59 and 39 ends were sequenced directly off the
ColoAd1 and Ad11p DNA (1 mg DNA per reaction).
In vivo and ex vivo testing
Mouse studies were performed as previously described [24] in
accordance with the institutional guidelines of the University of
Washington. All experiments involving animals were conducted in
accordance with the institutional guidelines set forth by the
University of Washington. Briefly, 8- to 12-week-old female
immunodeficient mice (CB-17/lcrCrl-scid-bgBR; CB-17; Charles
River Laboratories Inc., Wilmington, MA.) were housed in specific
pathogen-free facilities and infused with 2610
6 HT-29 cells
(human colorectal adenocarcinoma, ATCC# HTB-38) through a
permanently placed portal vein catheter. Fifteen days after tumor
cell transplantation, blood samples (80 ul) were obtained by
retrorbital bleeding and serum was obtained and stored at 280uC
for subsequent analyses. Preliminary studies determined that
(tumor-derived) serum human CEA levels become detectable at
day 15 after HT-29 cell transplantation. At day 16 and 17 post
tumor transplantation, mice received the indicated doses of viruses
(in 200 ul PBS) by tail vein injection. Control mice were injected
with 200 ul of PBS. At days 4, 8, 12, and 15 after virus injection,
mice were weighed and blood samples were collected. At day 15
after virus injection, mice were sacrificed, tumor-bearing livers
were micro-dissected and weighed and tumor burden was
expressed as the ratio of tumor per total liver weight. Serum
CEA levels were measured by ELISA (Calbiotech, Spring Valley,
CA) according to the manufacturer’s manual.
For clinical tissue biopsy, ex vivo culture and viral infectivity
analysis, an ex vivo culture system, using clinically derived tumor or
normal tissue biopsies, was developed. Tissue specimens were
collected and processed at the Veterans Affairs Palo Alto Hospital
(Palo Alto, CA) under the institutional review board-approved
procedure. All the clinical tissues were obtained with approval of
the research ethics committees and with informed consent. The
trial was carried out under the oversight of the Institutional
Review Boards of Stanford University and the Palo Alto Veteran’s
Administration Health Care System. Written consent was
obtained for use of the tumor samples. Immediately after surgical
removal the tissue specimens were dissected on ice and
homogeneous areas of tumor and non-tumor regions were
identified by a pathologist. By dicing the specimens into crossed
surgical blocks, cubes of less than 1 mm
3 were prepared, rinsed
and placed in 6-well plates in Iscove’s modified Dulbecco’s
medium (IMDM) supplemented with 5% FCS. Viral tissue
infection was then achieved by addition of 1610
10 particles to
each tissue sample. Virus was removed after 2 h, tissue washed
and fresh medium added to the wells (medium as before, but with
10 mM insulin and 1 mM hydrocortisone). The tissue specimens
were placed on Millicell 0.45 mm membrane culture inserts
(Millipore, MA, USA) inside 6-well plates and incubated at
37uC, 5% CO2 for the duration of the study.
After 24 h the media was removed for titering of PFU and the
tissue paraffin embedded. Evaluation of tissue survival, cytopathic
effect and general tissue/cell morphology was performed by
examination of Haematoxylin and Eosin (H/E) stained paraffin
sections. Sections were stained for CD46 expression with mouse
anti-human CD46 (RDI, Concord, MA) followed by anti-mouse
biotin-conjugated secondary antibody and developed with a
streptavidin-HRP complex and counterstained with Haematoxylin.
Statistical Analysis
In vivo values were expressed as mean+/2standard error of the
mean (SEM). Ex vivo data were expressed as mean+/2standard
deviation (stdev). Differences between groups were analyzed by
Mann-Whitney analysis. Values of p,0.05 were considered
statistically significant. MTS assays were assessed in quadruplicate,
and IC50 values were derived from dose response curves with R
2
value of 0.9 or greater. P values were calculated by Mann-
Whittney U-test. A P value of ,0.05 was considered statistically
significant. Each MTS assay was repeated at least 2–3 times, with
consistent results.
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